NEW YORK, Sept. 7, 2023 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( “PAVmed”), today announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study. This is the Company’s first report of prospective data from multiple physicians demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer; and supplements its recently released positive data from a retrospective analysis of EsoGuard’s clinical utility in firefighters. read more
Author: Harshal Chaudhari
The National Health Service (NHS) has released results from a trial study of a multi-cancer early detection test (MCED) named Galleri, developed by the California-based healthcare technology company Grail. This clinical laboratory blood test can detect up to 50 types of cancer and pinpoint their location within the body. The study, named SYMPLIFY, was a collaboration involving the University of Oxford and began in 2021. The Galleri test was found to be 85% accurate in determining the source of the cancer. The test’s overall sensitivity was 66.3%, ranging from 24.2% for Stage 1 cancers to 95.3% for Stage IV cancers.…
Early detection is crucial for effective cancer treatment, and liquid biopsies, which involve a simple blood draw, are emerging as a non-invasive method for cancer diagnosis using DNA or RNA sequencing. Assistant Professor Daniel Kim and his team are advancing liquid biopsy technologies by harnessing signals from RNA “dark matter,” a lesser-explored segment of the genome. Their research indicates that this genetic material is present in the blood of cancer patients and can be used to diagnose specific types of cancer, such as pancreatic, lung, and esophageal, early in their progression. The team’s RNA liquid biopsy platform, which detects both…
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Researchers from Helmholtz Munich and the University of Technology Dresden have demonstrated that artificial intelligence (AI)-based predictions can yield results comparable to clinical tests on CRC biopsies. These AI predictions can expedite the analysis of tissue samples, leading to quicker treatment decisions. This innovative model for biomarker detection marks a significant advancement towards precision therapy in oncology. The method, detailed in the journal Cancer Cell, utilizes “transformer networks,” a deep learning approach, to identify patterns and aid in cancer diagnosis. The new technique notably enhances previous methods for…
In the first edition of MedAI Roundup, which highlights the latest news and research in healthcare-related artificial intelligence each month: NYU Langone’s AI Initiative: NYU Langone introduced a tailored version of OpenAI’s ChatGPT and organized an AI “prompt-a-thon” where a team of employees experimented with the tool. JAMA’s AI Focus: JAMA released an editorial detailing its objectives for publishing research on AI in healthcare. The focus areas include clinical care, patient-centered care, healthcare quality, fairness in AI algorithms, medical education, clinician experience, and global solutions. Addressing Biased Clinical Data: A suggestion in the New England Journal of Medicine emphasized viewing…
Physician’s Weekly recently had a discussion with Dr. Satish SC Rao, an esteemed clinician from the American Gastroenterological Association (AGA). The conversation revolved around the role of NHE3 inhibitors in the treatment of IBS-C (Irritable Bowel Syndrome with Constipation). Dr. Rao provided his expert perspective on the topic. How do NHE3 inhibitors work?The goal of sodium hydrogen exchange 3 (NHE3) inhibition is to block sodium absorption in the intestinal lumen. Whenever sodium is retained inside the gut lumen, it draws water into the lumen, leading to fluid accumulation inside the gut. This fluid accumulation distends the gut, induces peristalsis, and…
Viome Life Sciences, a biotechnology company, received $86.5 million in an oversubscribed Series C funding round, which it will use to grow its business, the company announced Friday. The Bellevue, Washington-based startup sells at-home testing and health products to consumers through its website. It offers a full body health test, a gut health test and an oral health test. The tests then leverage AI to provide consumers with insights on what’s leading to microbial imbalances and inflammation, and then Viome offers personalized food lists, probiotics and prebiotics to support consumers’ health. It also has an oral and throat cancer diagnostic test, which…
NEW YORK – Grail has entered into a research collaboration with nonprofits the Whitman-Walker Institute and Cancer Support Community (CSC) to advance health equity in cancer screening through the use of multi-cancer early detection (MCED) testing in diverse patient populations, the partners said on Wednesday. The collaborative study, called INCLUDE (implementation and navigation of cancer liquid biopsy to understand diverse patient experiences), will conduct community outreach to build awareness of and increase early cancer screening, focusing on groups that have been historically underrepresented in clinical care and research. Eligible individuals will be invited by Whitman-Walker, which focuses on LGBTQ health,…
With $3.7 million in funding from the National Institutes of Health, Carolina launched in August a five-year project to establish the Center for Virtual Care Value and Equity. The grant from the National Center for Advancing Translational Sciences will support research on the use of online services, remote monitoring and text-based messaging to deliver health care services remotely. The center is led by Saif Khairat, associate professor and Beerstecher-Blackwell Distinguished Term Scholar in the UNC School of Nursing. Khairat’s projects have enhanced health care services and research within the digital health world. READ MORE
I’m starting this with a personal story. My mother was a New York City public school teacher for many years. When she joined the school system, part of the deal was that, when she retired, many of the costs of her traditional Medicare plans would be subsidized by her union and by the city. So far, so good. However, now the city, in order to save money, is moving all its retirees, including the public school teachers, to a Medicare Advantage plan. (If you don’t know what Medicare is, or the difference between traditional Medicare and Medicare Advantage, don’t worry…